No Picture
News

Brickell Biotech Doses First Subject in Phase 1 Study of DYRK1A Inhibitor BBI-02

Brickell Biotech, Inc. (“Brickell” or the “Company”) (Nasdaq: BBI), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases, […]